Regeneron Pharmaceuticals Inc. (REGN)

NASDAQ : Health Technology
Prev Close 284.18
Day Low/High 279.47 / 287.00
52 Wk Low/High 271.57 / 442.00
Avg Volume 757.00K
Exchange NASDAQ
Shares Outstanding 107.98M
Market Cap 31.23B
EPS 22.60
P/E Ratio 15.49
Div & Yield N.A. (N.A)

Don't Expect Any Apologies

Still, it's a good time to review what's happening, so we never forget.

How to Game This Clueless Market

As long as you use common sense, you will be able to profit.

Leadership Is Back

Welcome back to the airlines and the biotechs.

Resistance Is Futile

Resistance Is Futile

Here are three stock that have returned to former breakout levels.

Take Solace in Biotech

This group reminds us of our nation's innovative spirit and fabulous science.

What Has Kept People Out of Stocks

Sadly, these five themes have driven folks away from the market's remarkable five-year run.

Cramer: What's Working, What's Not

Yep, the bets for the rest of 2014 are being placed.

Today's Hero Stocks

Some plays that really shine, even in low volume.

Thank Self-Help, Not the Fed

The Burger King deal exemplifies companies helping themselves and the index.

Signs of Leadership Returning

Biotech stocks are thriving in a slower-growth, low-inflation world.

Finding Winning Charts Amid the Gloom

These quality names look appealing on the basis of 30-week moving average.

Two Giants Blindsided by Major Trends

McDonald's and GlaxoSmithKline are fighting against major turns of the tide.

Have to Own Your Trades

Have to Own Your Trades

LeBron back to Cleveland shows us what is important.

Valeant Is Hard to Stop

Cheap money and greed from the Allergan bidder's side are strong incentives.

Picking Up Where We Left Off

Another quarter, another run to record highs.

The Lesson of Today's Session

Become more aggressive about the real valuations of companies.

In Fact, There Is No Bubble, Part 4

Away from the techs and the biotechs, you will find an astounding uniformity among stocks.

The Blueprints for this Market (Part 5)

When it gets as bad as it is now, we tend not to even care if a company is profitable.

Get Used to the New Market Reality

Algos think faster and react faster than humans can.

Fitz Bits: The Biotech Wreck

Fitz Bits: The Biotech Wreck

These stocks are broken -- and you can't un-break them

Checking Regeneron for Symmetry

Taking a bigger-picture view of the biotech's weekly chart.

Regeneron upgraded at Citi

A Momentum Monsters Manifesto

This strategy is a hedge against momentum-oriented money managers -- nothing more, nothing less.

Biotech Remains on Fast Track

Even after a run, some stocks still offer growth.

John Carter Analysis: TSLA, SLV, PFE, QIHU, BIDU, REGN, TLT & SPY

John Carter Analysis: TSLA, SLV, PFE, QIHU, BIDU, REGN, TLT & SPY

We start the short week with some thoughts on TSLA earnings and the recent move in SLV. We also drill down into a few of our favorite stocks in whats otherwise a very uncertain market.

Momentum Monsters (Part 2)

Here are the next five names on my gunner-stock list.

A Surprising Leaderboard

These sectors have shown some fight.

Regeneron downgraded at Oppenheimer

I'll Still Trumpet These Stocks

I like living, breathing examples of growth stocks going right.